Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
New to MyHealth?
Manage Your Care From Anywhere.
Access your health information from any device with MyHealth. You can message your clinic, view lab results, schedule an appointment, and pay your bill.
ALREADY HAVE AN ACCESS CODE?
DON'T HAVE AN ACCESS CODE?
NEED MORE DETAILS?
MyHealth for Mobile
Stimulation of natural killer cells with an anti-CD137 antibody enhances the efficacy trastuzumab, cetuximab, and rituximab in HER2-expressing breast cancer, EGFR plus head and neck cancer, and CD20+lymphoma
Stimulation of natural killer cells with an anti-CD137 antibody enhances the efficacy trastuzumab, cetuximab, and rituximab in HER2-expressing breast cancer, EGFR plus head and neck cancer, and CD20+lymphoma Kohrt, H., Houot, R., Weiskopf, K., Goldsteini, M., Lund, P., Czerwinski, D., Sunwoo, J., Tedder, T., Chen, L., Levy, R. AMER ASSOC CANCER RESEARCH. 2012View details for DOI 10.1158/1538-7445.AM2012-LB-138
View details for Web of Science ID 000209701500249